The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, along with conventional treatments, makes the rheumatoid…
NASH is an increasingly prevalent disease characterized by excess lipid (steatosis) in the liver, resulting in inflammation and eventually liver fibrosis. Ensuing complications can include liver…
Heart failure is a major public health burden in China. With a rapidly rising urban population and a growing trend in unhealthy lifestyles, heart failure is expected to affect a sizable population…
Approximately 80% of rare diseases have a genetic etiology. Gene therapies hold the potential to transform the treatment of rare diseases and may provide a functional cure for some. However, these…
In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…
Among the four subtypes of non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma DLBCL is the most common in China. Rituximab (Roche’s MabThera, biosimilars) continues to dominate China…
Among the four subtypes of non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma DLBCL is the most common in China. Rituximab (Roche’s MabThera, biosimilars) continues to dominate China…
Even though obesity is a significant public health concern that poses a substantial socioeconomic burden on the U.S. healthcare system, the reimbursement environment for antiobesity agents is very…
2020 will be a turning point for the U.S. acute migraine market. Three novel therapies—Allergan’s Ubrelvy, Eli Lilly’s Reyvow, and Biohaven’s Nurtec ODT—entered the market in rapid…
Tumor necrosis factor-alpha (TNF-α) inhibitors (e.g., AbbVie’s Humira, Amgen’s Enbrel) and Janssen’s interleukin (IL)-12/23 inhibitor Stelara have been leading the U.S. psoriasis biologics…
MARKET OUTLOOK Rheumatoid arthritis (RA) is characterized by chronic and progressive joint inflammation that commonly leads to permanent, debilitating tissue damage and cartilage and bone…
Biosimilars of erythropoiesis-stimulating agents (ESAs) entered the European market a decade ago, but the FDA did not approve the first ESA biosimilar—Retacrit—until June 2018; it launched in…
Since the approval of the first biosimilar in Europe more than a decade ago, the adoption of biosimilars has been increasing among all specialties. The FDA approved Sandoz’s Zarxio (filgrastim)…
This content examines the market access factors that influence the success or failure of therapies for renal anemia. It is based on primary research with U.S. nephrologists and MCO pharmacy and…
Cancer pain is a complex form of chronic pain to treat because it typically involves mixed nociceptive and neuropathic pain resulting from multiple causes (e.g., chemotherapy, metastases)…